No. 3 / 2025
Center for Molecular Medicine

CMM News

Page 2

Swedish Research Council Grants

Page 11

Competitive SSF Grant for “Instrument, Technology, and Method Development”



Page 19

Call for proposals – CMM postdoc positions

Download this newsletter here

Editor: Magdalena Lindén
Layout: Edna Fagerstedt

CMM

Swedish Research Council Grants



The Swedish Research Council has decided on the allocation of funding among the proposed projects in medicine and health applied for in 2025.

This year, the number of applications in medicine and health has increased significantly compared to last year for all types of grants, according to a press release from the Swedish Research Council. In the Swedish Research Council's (VR) call for grants in medicine and health, just over SEK 1.2 billion has been granted for the next six years.

The decision includes the following grants to CMMers, amounting to SEK 64.45 million and spanning a period of three to five years:

Hanna Brauner received SEK 11,100,000 for six years as a grant for research time as well as SEK 5,400,000 for four years as a project grant for the project “Cutaneous lymphoma – clinical and experimental studies of mechanisms of origin, prognostic factors, and long-term effects”.

Kristina Broliden received a SEK 5,400,000 project grant for four years for the project titled: “Defense mechanisms of the genital mucosa in vulvovaginal candidiasis - implications for HIV susceptibility”.

Susanne Gabrielsson received a SEK 3,000,000 project grant for three years for the project titled: “Mechanisms of how extracellular vesicles influence immune response and cancer growth.”

Leo Hanke received a SEK 5,400,000 project grant for four years for the project titled: “Fc receptor binders for precise recruitment and activation of the immune system.”

Taras Kreslavskiy received a SEK 8,500,000 project grant for five years for the project titled: “To analyze the unusual antigen receptor specificities of gamma-delta T cells in health and disease.”

Philippe Melas received a SEK 2,250,000 project grant for three years for the project titled: “Subcellular proteomics-driven drug repurposing for alcohol dependence: A human-focused 3R strategy.”

Ann Nordgren received a SEK 5,400,000 project grant for four years for the project titled: “The significance of congenital genetic factors in childhood cancer.”

Tomas Olsson received a SEK 3,000,000 project grant for three years for the project titled: “New autoantigens and immunological cross-reactions against pathogens in multiple sclerosis.”

Georg Schett received a SEK 3,000,000 project grant for three years for the project titled: “Immune profile in lymph nodes after effective B-cell depletion in autoimmune disease”.

Eduardo Villablanca received a SEK 6,000,000 project grant for four years for the project titled: “Towards an individualized treatment of ulcerative colitis: Mapping molecular processes of inflammation and healing.” **Eduardo** also received a network grant for planning future clusters of excellence for pioneering technologies consisting of SEK 1,200 000 for 6 months for a network centered on the project "From algorithm to organ: AI-guided development of next-generation human model systems".

Caroline Wasén received a SEK 6,000,000 establishment grant for four years for the project titled: “Prevent brain atrophy in rheumatoid arthritis”.

New CMMers

Yvonni Chrysostomidou is a new research assistant in Per-Johan Jakobsson's research group at CMM. Yvonni holds a BSc in Chemistry from University of Ioannina, Greece and recently completed her Master's studies in Analytical Chemistry at Stockholm University. She will be working on the development of an LC-MS based metabolomics method to analyze the effects of bioactive molecules derived from plants used in Traditional Chinese Medicine (TCM).

Mora Massaro is a new postdoctoral fellow in Villablanca's CMM group. She earned a degree in Biology from the National University of Mar del Plata and a PhD in Chemical Biology from the University of Buenos Aires (Argentina). Her research focuses on the role of plasma cells in inflammatory bowel disease, with primary interests in mucosal healing and glycobiology.

Silvia D'Orso is a postdoctoral researcher in the group of Fredrik Piehl, under the supervision of Nicolas Ruffin. Silvia will work on characterizing EBV-infected cells in multiple sclerosis and the impact of B-cell depleting therapies.

Welcome to CMM!

New CMMers

Samuel Villalobos Vargas, a Biotechnology student from the Costa Rica Institute of Technology has recently joined the CMM Team of Gustavo Monasterio. At CMM he will work on his final graduation project which will focus broadly on understanding how epithelial tissues respond to sympathetic modulation and inflammatory stimuli, particularly in salivary glands and the intestinal mucosa. As part of this project, he will be involved in techniques such as immunohistochemistry, spatial transcriptomics, and the use of mouse models.

Mahya Karami is a visiting student in Eduardo Villablanca's lab. During her master thesis project she will be working with Bianca Kern, PhD student, focusing on studying the role of LXR signaling in tumor suppression. Her work focuses on investigating the underlying molecular pathways and immune mechanisms using animal models, with the aim of better understanding how LXR activation influences cancer development.

Welcome to CMM!

Zhichao Zhou was appointed as CMM Group Leader as of October 8th 2025

APPOINTMENTS

Zhichao Zhou's research group (Cardiometabolic Vascular Medicine) is dedicated to uncovering novel molecular drivers of cardiovascular dysfunction, with the goal of identifying actionable therapeutic targets and reliable biomarkers to improve outcomes in cardiometabolic disease.

Specifically, Zhichao Zhou's CMM group studies:
- Endothelial dysfunction: Investigating how proteins, enzymes, and non-coding RNAs within endothelial cells contribute to atherosclerosis and cardiometabolic disease.
- Red blood cell (RBC)-derived non-coding RNAs in vascular regulation: Investigating how ncRNAs and their extracellular vesicles influence vascular pathology in diabetes, and assessing their potential as biomarkers for predicting cardiovascular complications.
- Purinergic signaling and hypoxia: Examining how RBC-derived ATP regulates vascular tone under hypoxic conditions and how disruptions in this signaling contribute to vascular dysfunction in cardiometabolic disease.

Currently, the group consists of the following members:
Zhichao Zhou, MD PhD, Group Leader
Tong Jiao, MD PhD, Postdoc
Álvaro Santana-Garrido, PhD, Postdoc
Eftychia Kontidou, Ms, doctoral student
Rawan Humoud, MD, doctoral student
Marita Wallin, Biomedical analyst

The group is located in BioClinicum, floor 8 (J8:20, Cardiology, BioClinicum, Karolinska University Hospital, Akademiska Stråket 1)

Keira Melican was appointed as CMM Group Leader as of October 8th 2025

APPOINTMENTS

Keira Melican's research group investigates how the skin's microbiota and immune system work together to defend against Staphylococcus aureus infections. They study how S. aureus transitions from a harmless commensal to an invasive pathogen, and how the natural microbial community helps suppress this shift. This work includes the study of quorum sensing and antimicrobial peptide production. By uncovering the skin microbiota's intrinsic antimicrobial mechanisms and exploring ways to alter the skin microenvironment, they aim to develop innovative strategies to control MRSA.

In parallel, they examine how the innate immune system distinguishes commensal organisms from pathogens. By identifying the skin-resident immune cells that mediate this recognition and testing immunomodulatory treatments, the research group seeks to enhance natural immunity and improve the effectiveness of antimicrobial therapies.

Currently, the group consists of the following members:
Keira Melican, Associate Professor, Group Leader
Andreas Brutscher, PhD student
Julia Lang, Postdoc
Mariam Shahata, PhD student

The group is located in the CMM L8 building, floor 3.

Ulf Hedin appointed Baszucki Visiting Professor at Stanford University



The Vascular Surgery lab at Stanford, Ulf Hedin second from the left, Dr Jason Lee second from the right. Photo: n/a.

APPOINTMENTS

On October 21–22, Ulf Hedin, Professor of Experimental Vascular Surgery at the Department of Molecular Medicine and Surgery, and CMM Group Leader, visited Stanford University in San Francisco.

Ulf Hedin was invited as this year's Baszucki Visiting Professor at the Baszucki Research Day 2025. He held lectures on “Precision Medicine for Carotid Disease” for the vascular surgery department and the research group, and at the Grand Rounds, with 200 participants from the surgery department, he gave a lecture on “Biobanking – a Gold Mine for Development of Research and Clinical Care”.

The visit was arranged by the Department of Vascular Surgery under the leadership of Dr. Jason Lee, with support from the Baszucki Family Research Fund.

Xinxin Luo recieves Dimitri Chorafas Prize 2025

AWARDS

Xinxin Luo, postdoctoral researcher in Eduardo Villablanca's Group at CMM, has been awarded the Dimitris N. Chorafas Prize 2025. The prize of USD 10,000 is intended for recent PhD graduates or doctoral students in their final year of doctoral studies. The aim is to encourage young, promising researchers. Xinxin Luo is recognised for her research on how inflammation, tissue damage and healing processes interact in the intestine.

Xinxin Luo was awarded the prize for her thesis 'The role of Liver X Receptor (LXR) in intestinal inflammation and mucosal healing'.

Xinxin Luo's research focuses on understanding how inflammation, tissue damage and healing processes interact in the intestine, with a particular focus on the role of the liver X receptor (LXR) in intestinal recovery and immune regulation.

The jury's motivation:
"For her groundbreaking research contributions that comprehensively explore the intricate relationship between inflammation, tissue damage and repair mechanisms within the intestinal environment. Xinxin Luo has demonstrated scientific excellence through production of impressive publications, demonstrating originality and innovation in methodology development, as well as effective interdisciplinary scientific collaborations.

Xinxin Luo. Photo: Shiliang Guo

Her doctoral research is testament to the inherent qualities of an exceptional early-career scientist, and outlines targeted therapeutic strategies that could significantly improve related intestinal disorders outcomes."

Tilen Tršelič is the winner of Cilla Weigelt Award 2025

AWARDS

CMMer Tilen Tršelič has received the Cilla Weigelt 2025 Award for his research on Sjögren's disease. The prize is SEK 60,000.

Sjögren's disease, is an autoimmune condition in which the immune system attacks the glands responsible for producing moisture in the body, such as the tear and salivary glands. Sjögren's disease is a relatively common autoimmune disease, affecting an estimated 0.1% to 1% of the global population. It occurs predominantly in women, who develop it about 9 to 10 times more frequently than men.

Tilen Tršelič is a PhD student in Marie Wahren Herlenius CMM Group and at the Division of Rheumatology, Dept of Medicine, Karolinska Institutet, and in his main project he studied how a specific gene, DIORA1, contributes to autoimmune diseases such as Sjögren's disesase.

The Cilla Weigelt award aims to encourage and support PhD students investigating molecular mechanisms of relevance to rare and undertreated diseases. An award ceremony/seminar at Chiesi Global Rare Diseases R&D offices on Campus Solna is planned later this fall.

"Receiving the Cilla Weigelt Award is a true honour. It is incredibly meaningful to see our work on the molecular mechanisms of autoimmune diseases recognized in this way. I also want to stress that this award is not only a reflection of my own efforts but also of the many mentors, collaborators, and colleagues who have supported and inspired me throughout my PhD so far. Importantly, the award will give me the chance to build new collaborations and explore fresh ideas for the next phase of my research – opportunities that will likely shape my development as a scientist. In short, it is both a recognition of the journey so far and a catalyst for what comes next" says Tilen Tršelič.

Tilen Tršelič. Photo: Miranda Stiernborg

His research is focused on the molecular and cellular function of an uncharacterized gene named family of sequence similarity 167 member A (FAM167A). FAM167A has been linked to Sjögren's disease in genetic association studies and has homology with FAM167B. Both genes encode proteins of unknown functions and have been given the names Disordered autoimmunity 1 and 2 (DIORA1 and 2), respectively. The results of Tilen's work were recently published in *PNAS*. In the upcoming Christmas edition of CMM News you will be able to read more about DIORA1 and the study by Tršelič *et al*.

About the Cecilia Weigelt Prize:
Cecilia "Cilla" Weigelt (1969–2021), Ph.D. in Clinical Immunology, led Cell Biology at HemeBiotech/Zymenex (later acquired by Chiesi). During this time, she made significant contributions to several drug discovery and development projects focused on the treatment of rare diseases. Cilla always supported younger researchers and was driven by the goal of helping patients who lacked adequate treatment for devastating illnesses. She passed away at 51 after a long battle with breast cancer. To honor her legacy, the Cilla Weigelt Prize was created by Chiesi, the Structural Genomics Consortium, and her family and friends to inspire doctoral students. The prize is administered by the Center for Molecular Medicine Foundation at Karolinska Institutet and Karolinska University Hospital, with additional support from Aled Edwards (Toronto), Johan Weigelt (Stockholm), and MRCS AB (Michael Sundström, Stockholm).



Grants from Cancerfonden

Image: iStock.

FUNDING AND GRANTS

In Cancerfonden's latest call, 8 researchers from CMM received SEK 21.35 million for the years 2026-2028.

Joakim Dahlin received SEK 3,000,000 for two years or the project "Data-driven dissection of systemic mastocytosis and chronic myeloid leukemia: from mechanisms to therapies".

Susanne Gabrielsson received SEK 4,500,000 for two years for the project "Mechanisms by which extracellular vesicles function in immunotherapy and modulate cancer progression".

Per-Johan Jakobsson received SEK SEK 3,000,000 for three years for the project "Investigating the immunomodulatory effects of mPGES-1 inhibition in cancer treatment to improve therapeutic efficacy and safety".

Annika Lindblom received SEK 1,000,000 for one year for the project "Colorectal cancer predisposition and prevalence".

Stephen Malin received SEK 3,000,000 for two years for the project "Lipid-immune interactions in the early initiation of hepatocellular carcinoma".

Magdalena Paolino received SEK 1,600,000 for two years for the project "Leveraging atypical deubiquitinases for novel osteosarcoma treatment strategies".

Richard Rosenquist Brandell received SEK 7,500,000 for three years for the project "Charting the complex molecular landscape in chronic lymphocytic leukemia – the path towards precision medicine", as well as funding for the Swedish CLL Group, consisting of SEK 750,000 for three years.

Eduardo Villablanca received SEK 4,500,000 for three years or the project "Dissecting the role of Liver X Reeptor in promoting antitumor responses".

CMM Research Group Leader Vladana Vukojevic Awarded SSF Grant for “Instrument, Technology, and Method Development”

FUNDING AND GRANTS

In a highly competitive call, 12 projects out of 263 selected for funding, CMM Research Group Leader Vladana Vukojevic was awarded SEK 8.5 million by the Swedish Foundation for Strategic Research (SSF) for her project “Time-resolved nano-diagnostics with ultimate sensitivity”.

This three-year grant supports the development of new tools designed to enable technical breakthroughs, advance scientific research, and improve medical diagnostics, while also fostering the recipients’ career development. We congratulate Vladana on this achievement and look forward to **presenting her research in the Christmas edition of CMM News.**

Vladana Vukojevic. Photo: Private.

Grant to Nicolas Ruffin from Neuroförbundet

FUNDING AND GRANTS

Nicolas Ruffin, Docent in Immunology has received a SEK 250,000 stipend from Neuroförbundet Stockholm, a patient organization. His project entitled "Multiple sclerosis: Could a common virus be the cause?" focuses on the interactions between EBV and the host immune response associated with multiple sclerosis.

Nicolas Ruffin to the left. Photo: Private.

Some publications

CMMers IN BOLD

Argyriou A, Wadsworth MH, Fienman J, Gonzalez-Sanchez AC, Ghannoum S, Krishna C, **Gerstner C, Horuluoglu B, Sijbranda M, Rönnblom L, Eloranta ML, Wahren-Herlenius M, Hensvold A, Turcinov S,** Winkler A, **Malmström V, Chemin K.** Innate immune cell subsets are enriched in synovial fluid of ACPA-negative rheumatoid arthritis and characterized by distinct type I IFN gene signatures. *Ann Rheum Dis.* 2025 Oct 3:S0003-4967(25)04299-2. doi: 10.1016/j.ard.2025.07.029. Online ahead of print.

Behere A, Mildner H, Peralta Garcia I, Pérez Bucio C, **Lundberg I, Horuluoglu B*, Landegren N***. Idiopathic inflammatory myopathies lack neutralising autoantibodies to type- I, II and III interferons. *RMD Open.* 2025 Sep 25;11(3):e005836. doi: 10.1136/rmdopen-2025-005836.

Eliasson I, Wyss K, Tafesse Bogale R, Forsblom S, Lindquist E, Rönnberg C, Hansson M, Beshara S, Nordling I, Hertting O, Wångdahl A, **Färnert A**. Clinical Findings in Migrants With Asymptomatic Plasmodium Infections. *Open Forum Infect Dis.* 2025 Sep 2;12(9):ofaf525. doi: 10.1093/ofid/ofaf525. eCollection 2025 Sep.

Galindo-Feria AS, Kumar RS, Dubnovitsky A, Gerstner C, Kozhukh G, Van Vollenhoven A, Diaz Boada JS, Ramsköld D, Achour A, Dastmalchi M, Reid H, Sandalova T, Rossjohn J, **Chemin K, Malmström V*, Lundberg IE*, Horuluoglu B**. Autoreactive T cells identified in patients with anti-Jo1+ antisynthetase syndrome recognise a new epitope on histidyl t-RNA synthetase. *Ann Rheum Dis*. 2025 Oct 25:S0003-4967(25)04429-2. doi: 10.1016/j.ard.2025.09.015. Epub ahead of print.

Geara J, Luo L, Parlak O, Sommar P, **Xu Landén N**. Poly-L-Lactic Acid Microspheres Promote Skin Rejuvenation via Enhanced Fibroblast Function. *J Biomed Mater Res A.* 2025 Nov;113(11):e38017. doi: 10.1002/jbm.a.38017.

Gonzalez-Chapa JA, **Horuluoglu B, Notarnicola A**, Rathee A, Kaur N, Stultz RD, Christopher-Stine L, Albayda J, Nennesmo I, **Lundberg IE**, Lood C. N-formyl methionine peptide-driven neutrophil activation in idiopathic inflammatory myopathies. *Rheumatology* (Oxford). 2025 Sep 15:keaf495. doi: 10.1093/rheumatology/keaf495. Epub ahead of print.

Hedström AK, **Olsson T, Piehl F, Alfredsson L**. Beneficial impact of physical activity on multiple sclerosis disability progression. *J Neurol Neurosurg Psychiatry.* 2025 Sep 23:jnnp-2025-336738. doi: 10.1136/jnnp-2025-336738. Online ahead of print.

Hunt M, Vincent AE, McNiff MM, Ettridge G, Sabin C, Winston A, Payne BAI - Mitochondrial respiratory chain deficiency is associated with an impaired skeletal muscle regenerative response and fibrosis in older men with HIV. *npj Aging 11, 79* (2025). https://doi.org/10.1038/s41514-025-00273-6

Laffita-Mesa JM, Paucar M, **Svenningsson P**. Repeat Variants, Biomarkers, and Molecular Signatures in Parkinson's Disease: ATXN2, ATXN3, CACNA1A, PRNP, TBP, C9ORF72, TOMM40, APOE, and POLG-A Swedish Perspective. *Int J Mol Sci.* 2025 Sep 20;26(18):9213. doi: 10.3390/ijms26189213. PMID: 41009775 Free PMC article.

Liu J; **Paolino M**. Ubiquitination in macrophage plasticity: from inflammatory to immunometabolic pathways. *Front Immunol.* 2025; 16:1621328

Pedersen A, **Trogu F**, Armiento M, **Fink K**, Frisell T, **Piehl F**. Correlates of patient reported quality of life in a large multiple sclerosis cohort encompassing the COVID-19 pandemic period. *Mult Scler Relat Disord.* 2025 Sep 13;104:106755. doi: 10.1016/j.msard.2025.106755. Online ahead of print.

Qu H, Neog M, Palmblad K, Sundberg E, Lövquist A, Melén E, Aulin C, **Harris HE**. Cross-Sectional and Longitudinal Immunoprofiling of Oligoarticular Juvenile Idiopathic Arthritis Reveals Different Patterns in Synovial Fluid and Plasma. *Scand J Immunol.* 2025 Oct;102(4):e70055. doi: 10.1111/sji.70055.

Some publications

CMMers IN BOLD

Sturchio A, Paslawski W, Khosousi S, Markaki I, Nalls MA, Singleton AB, Iwaki H, **Svenningsson P**. High Cerebrospinal DOPA Decarboxylase Level Predicts Cognitive Decline in Parkinson's Disease. *Mov Disord Clin Pract.* 2025 Sep 24. doi: 10.1002/mdc3.70367. Online ahead of print.

Shang MM, Liu Z, Knezevic B, Westerberg CM, Panda SK, Fang H, **Landén NX, Sundström M**, Knight JC, **Berg L**. Combining computational target prioritization and a B cell maturation assay for target evaluation studies in systemic lupus erythematosus. *Transl Res.* 2025 Sep 9;283:36-46. doi: 10.1016/j.trsl.2025.09.002. Online ahead of print.

Tršelič T, Pelo N, Martin de Fremont G, Iyer VS, Richardsdotter Andersson E, Ottosson V, Frei DA, Baas E, **Nyberg WA, Thorlacius GE, Mentlein L, Boddul SV, Sandu I, Velasquez Pulgarin D,** Végvári Á, **Gerlach C, Wermeling F,** Sunnerhagen M, Wallner B, **Espinosa A, Wahren-Herlenius M**. Autoimmunity-associated DIORA1 binds the MRCK family of serine/threonine kinases and controls cell motility. *Proc Natl Acad Sci U S A*. 2025 Oct 7;122(40):e2426917122. doi: 10.1073/pnas.2426917122. Epub 2025 Oct 3.

Zhang Z; Xie Y; Yi Q; Liu J; Yang L; Wang R; Cai J; Li X; Feng X; Yao S; Pan Z; **Paolino M***; Zhou Q.*. PEAK1 maintains tight junctions in intestinal epithelial cells and resists colitis by inhibiting autophagy-mediated ZO-1 degradation. *Nat Commun.* 2025; 16(1):6777

Mini abstracts

CMMers IN BOLD

Mini abstract:
In this review, we've highlighted the evolving landscape of B cell biology in IBD, emphasizing the need for selective therapeutic approaches that distinguish between protective and pathogenic B cells. Understanding spatial, phenotypic, and temporal B cell dynamics will be essential for developing selective, precise immunotherapies tailored to chronic intestinal inflammation.

Publication:
B cells in inflammatory bowel disease. **Castillo FA, Kern BC, Villablanca EJ.** *Immunology letters* 2025 08; 277:107071.



Mini abstracts

CMMers IN BOLD

Mini abstract:
We developed a transgenic zebrafish model enabling controlled intestinal epithelial ablation and regeneration. Single-cell RNAseq and imaging identified macrophage accumulation and igfbp1a upregulation as key regenerative mechanisms. This platform facilitates mechanistic insights and high-throughput screening for modulators of mucosal healing.

Publication:
A zebrafish model of intestinal epithelial damage reveals macrophages and igfbp1a as major modulators of mucosal healing. **Morales Castro RA, Kern BC, Díaz-Basabe A,** Meinen ER, Zhao D, Zhou Y, **Castillo F, Monasterio G**, Farcas V, Chávez MN, **Fransson J, Villablanca EJ.** *Mucosal Immunol.* 2025 Aug;18(4):836-847.



CMM Seminar Series with Ulf Landegren

CMM EVENTS AND OUTREACH

On November 19th CMM hosted Ulf Landegren, MD and Professor in Molecular Medicine at the Department of Immunology, Genetics and Pathology, Uppsala University, as well as inventor, and entrepreneur. The talk, titled "Tools for a molecular medicine", was fully booked (and overbooked), and as expected, also inspiring and entertaining to listen to.

The seminar was followed by a networking reception where the audience had the opportunity to chat to the speaker.

Photos: Magdalena Lindén.

Preprint Club

CMM EVENTS AND OUTREACH



The preprint club is back!! Are you a PhD student, a postdoc, or just found of immunology? Welcome every Wednesday at 16h00 @CMM. Take the opportunity to join a cross-institution initiative and participate to an innovative community-based review approach.

Register here: https://survey.ki.se/preprintclub2025

More information and latest highlights in our renewed website: https://www.preprintclub.com/

CMM Junior Seminar Series Special edition

UPCOMING EVENTS

December 12th at 15:00-16:30
CMM Lecture Hall

Erdem Aybay:
“Targeting PGE2 to enhance anti-tumor treatments”

Prof. Olle Kämpe:
“My years in the Nobel Committee”

Join us for a special holiday edition of the series! We will have two exciting talks and celebrate the holidays with some bubble afterwards. Do not miss this unique chance to learn about anti-tumor therapies and the inner workings of the Nobel Committee in one stimulating session.

The CMM Junior Seminar Series aims to provide a platform for young researchers - primarily PhD students and postdocs - to showcase the exciting work being done within the CMM community and advertise collaboration opportunities.

Contact us to join the organizing committee!

luis.santos@ki.se
sofija.sundman@ki.se

After the seminar there will be bubble & pizza mingle.

Call for proposals – CMM postdoc positions



The CMM Board of Directors have approved funding for two postdoctoral positions at CMM to support and strengthen collaborative and cross-disciplinary research at CMM.

These general provisions apply:

- Eligible applicants are CMM Group and Team leaders based at CMM, Bioclinicum or Biomedicum, except for the CMM Steering Group members.
- The proposed projects must be aligned with CMMs mission and goals, with translational outputs and goals.
- One project should be aligned with the CMM Dark Immunome project, and the other having a clear clinical research focus.
- Cross-disciplinary proposals involving collaborations between several groups at CMM will be prioritized.
- The proposed project should be carried out over a two-year period, and the Group or Team Leader applicant must serve as the main supervisor for the postdoc.
- Supervisor and postdoc of successful proposals must report progress two times/year to the CMM Steering Group, and funding could be terminated if progress is clearly below expectations.
- The maximum financial contribution from CMM is 1,72 MSEK for each two-year postdoc position and can be used for salary and project-related running costs.
- The postdoc should be employed on a fixed-term project basis, limited to a maximum of two years. Employment can be at Karolinska Institutet, Karolinska University Hospital or CMM.
- The funding cannot be used for stipend(s).

Application:

To submit an application please send the following documents in English in a single pdf file to Kristina.edfeldt@cmm.se latest on 31 January 2026. Research proposal of maximum three A4 pages in Arial font size 11, with single line spacing and 2,5 cm margins, references (font size 9) and any illustrations included. The application should be structured in the following sections with at least two pages on sections 4 & 5:

1. Purpose and aims
2. Current state-of-the-art
3. Significance and scientific novelty
4. Project description including theory and methodology
5. Cross-disciplinarity and collaborations
6. References

Main applicant CV of maximum one A4 page incl. 5 selected publications.

If applicable, postdoc candidate CV of maximum one A4 page incl. 5 selected publications.

Proposals will be reviewed and evaluated by the CMM Steering Group.

Note that this call for proposal is a one-off opportunity and the duration of the postdoc positions cannot be extended beyond the two-year duration.

Deadline for submitting contributions to the Christmas Edition of CMM News:
12 December 2025

Center for Molecular Medicine Foundation
L8:05 | Karolinska University Hospital
SE-171 76 Stockholm, Sweden
E-mail: communication@cmm.se

Editor: Magdalena Lindén
Layout: Edna Fagerstedt

CMM